D-0034-2018 Class III Terminated
FDA drug recall D-0034-2018 was initiated by AbbVie Inc. on Sep 8, 2017 and is designated Class III. Reason for recall: Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions. The recall status is terminated (terminated Apr 23, 2018). Affected quantity: 48 cartons (30 foil packets per carton).
Recall details
- Product Type
- Drugs
- Report Date
- Nov 1, 2017
- Initiation Date
- Sep 8, 2017
- Termination Date
- Apr 23, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 48 cartons (30 foil packets per carton)
Product description
AndroGel (testosterone gel) 1.62%, 40.5mg in 2.5g aluminum foil packet, 30 Packets per carton. Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064 USA. NDC: 0051-8462-30
Reason for recall
Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.
Distribution pattern
AZ
Code information
Lot: D60010A, EXP. 01/2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0034-2018
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for AbbVie Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.